Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
8650
Trial Sponsor
Clinical Trial Start Date
2002
0Primary Completion Date
2006
0Study Completion Date
2006
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Procedure0
Drug0
Intervention Name
aromatase inhibition0
antiestrogen therapy0
endocrine therapy0
toremifene0
letrozole0
hormone therapy0
atamestane0
Interventional Trial Phase
Phase 30
Participating Facility
Last Updated
July 31, 2015
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Quadruple0
Masked Party
Participant0
Care Provider0
Investigator0
Outcomes Assessor0
Study summary
The purpose of this study is to determine whether the first line combination hormonal therapy of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another approved drug, letrozole (Femara®), in delaying the growth of breast cancer in postmenopausal patients with locally advanced or metastatic breast cancer, and whether the side effects of the combination are different from the side effects of letrozole.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
